Novavax (NasdaqGS:NVAX) reported a surprise profit for the fourth quarter, alongside revenue that was above prior expectations. The company is shifting its business model by transferring ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending ...

European regulators cleared Moderna’s first-of-its-kind vaccine as US approval remains uncertain. On Friday, Moderna’s ...

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67 ...

Mpox vaccination significantly reduces disease severity compared with no vaccination, although protection may wane 2 years after the last dose.

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...

Novavax shares jump 21% after posting a surprise profit and 67% revenue growth, while outlining lower 2026 revenue guidance.

A Maryland biotech raised its revenue guidance for the year, thanks largely to some hefty pharma deals it’s betting will pay off.

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.